

Effectiveness of protease inhibitor/nucleos(t)ide reverse transcriptase inhibitor-based second-line antiretroviral therapy for the treatment of HIV-1 infection in sub-Saharan Africa: systematic review and meta-analysis

Authors

Alexander J. Stockdale^{1,2}, Matthew J. Saunders³, Mark A. Boyd^{4,5}, Laura J. Bonnett⁶, Victoria Johnston⁷, Gilles Wandeler^{8,9}, Annelot F. Schoffelen¹⁰, Laura Ciaffi¹¹, Kristen Stafford¹², Ann C. Collier¹³, Nicholas I. Paton¹⁴, Anna Maria Geretti²

Affiliations

¹Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre, Malawi;

²Institute of Infection & Global Health, University of Liverpool, Liverpool, United Kingdom;

³Section of Infectious Diseases and Immunity and Wellcome Trust-Imperial College Centre for Global Health Research, Imperial College London, London, United Kingdom

⁴Kirby Institute for Infection and Immunity, University of New South Wales, Sydney, Australia;

⁵Lyell McEwin Hospital, University of Adelaide, Adelaide, Australia;

⁶Department of Biostatistics, University of Liverpool, Liverpool, United Kingdom;

⁷London School of Hygiene and Tropical Medicine, London, United Kingdom;

⁸Institute of Social and Preventative Medicine, University of Bern, Bern, Switzerland;

⁹Department of Infectious Diseases, Bern University Hospital, Bern, Switzerland;

¹⁰Department of Infectious Diseases, University Medical Centre Utrecht, Utrecht, the Netherlands;

¹¹UMI 233 - Institute de Recherche pour le Développement (IRD) U1175 Institute National de la Santé et de la Recherche Médicale (INSERM) - University of Montpellier, Montpellier France;

¹²Institute of Human Virology, University of Maryland School of Medicine, Baltimore, United States of America;

¹³University of Washington School of Medicine, Seattle, United States of America;

¹⁴Yong Loo Lin School of Medicine, National University of Singapore, Singapore.

© The Author(s) 2017. Published by Oxford University Press for the Infectious Diseases Society of America.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

Corresponding author:

Prof Anna Maria Geretti

Department of Clinical Infection, Microbiology and Immunology

Institute of Infection and Global Health, University of Liverpool

8 West Derby Street

L69 7BE, United Kingdom

+44 151 795 9665

geretti@liverpool.ac.uk

Running title:

Second-line ART in sub-Saharan Africa

Summary

In sub-Saharan Africa, second-line ritonavir-boosted protease inhibitor-based antiretroviral therapy led to virological suppression in 69.3% at week 48 and 61.5% at week 96, based on an intention-to-treat meta-analysis of 4558 participants (14 studies) and 2145 participants (8 studies) respectively.

ABSTRACT

Background

In sub-Saharan Africa, 25.5 million people are living with HIV, representing 70% of the global total. The need for second-line antiretroviral therapy (ART) is projected to increase in the next decade in keeping with the expansion of treatment provision. Outcome data are required to inform policy.

Methods

We performed a systematic review and meta-analysis of studies reporting the virological outcomes of protease inhibitor (PI)-based second-line ART in sub-Saharan Africa. The primary outcome was virological suppression (HIV-1 RNA <400 copies/ml) after 48 and 96 weeks of treatment. The secondary outcome was the proportion of patients with PI resistance. Pooled aggregate data were analysed using a DerSimonian-Laird random effects model. PROSPERO registration: CRD42016048985.

Results

By intention-to-treat, virological suppression occurred in 69.3% (95% confidence interval 58.2, 79.3) at week 48 (4558 participants, 14 studies), and in 61.5% (47.2, 74.9) at week 96 (2145 participants, 8 studies). Pre-existing resistance to the nucleos(t)ide reverse transcriptase inhibitors (NRTIs) increased the likelihood of virological suppression. Major protease resistance mutations occurred in median 17% (IQR 0-25) of the virological failure population and increased with duration of second-line ART.

Conclusions

One third of patients receiving PI-based second-line ART with continued NRTI use in sub-Saharan Africa did not achieve virological suppression although among viraemic patients protease resistance was infrequent. There remain significant challenges in implementation of viral load monitoring. Optimising definitions and strategies for management of second-line ART failure is a research priority.

Keywords:

HIV; second-line antiretroviral therapy; protease inhibitor; sub-Saharan Africa; drug resistance

INTRODUCTION

The number of people receiving ART in sub-Saharan Africa increased from 7.5 million in 2010 to 17 million in 2015[1], and expanded treatment access has led to substantial gains in life expectancy.[2] UNAIDS aspires to further, fast-tracked improvements, with a target for 90% of patients knowing their HIV status, 90% being on ART, and 90% showing virological suppression by 2020.[1] The World Health Organisation (WHO) has advocated a public health approach to HIV control in sub-Saharan Africa, centred on standardised regimens for first-line and second-line therapy, and since 2015, on prompt ART initiation regardless of CD4 cell counts.[3] Recommended first-line regimens comprise two NRTIs such as tenofovir disoproxil fumarate (TDF) and lamivudine, and a non-nucleoside reverse transcriptase inhibitor (NNRTI), principally efavirenz.[3] Current recommended second-line regimens include two NRTIs such as zidovudine with lamivudine, and a boosted PI, with lopinavir/ritonavir or atazanavir/ritonavir preferred. A recent network meta-analysis has highlighted the current lack of evidence for alternative second-line regimens, besides lopinavir/ritonavir with raltegravir.[4] As NRTIs are continued in second-line ART, NRTI resistance acquired during first-line ART might represent an important determinant of efficacy.[5, 6]

In 2013 WHO recommended adoption of plasma viral load monitoring to enable early identification of treatment failure and appropriately guide treatment changes.[3] The level of implementation varies across the region, and even in settings with access to routine viral load testing, delays in switching to second-line ART are common.[7] With further expansion in ART use, an increasing number of people in sub-Saharan Africa are at risk of treatment failure and drug resistance.[8]

In order to inform policy related to treatment selection, monitoring, patient management, and access to third-line therapy, systematically collated data on outcomes of second-line ART, impact of prior NRTI resistance, and risk of emergent protease resistance are needed. The aim of this study is to provide a comprehensive overview of data on effectiveness of second-line ART in sub-Saharan Africa and to present pooled estimates of virological and resistance outcomes.

METHODS

Search strategy and selection criteria

PubMed, EMBASE, the Cochrane Register of Controlled Trials, Scopus and Web of Science were searched for articles published from 1 January 1996 to 28 July 2017 according to a predefined strategy (Supplementary table 1). References cited in the selected articles and abstracts from the International AIDS Society Conference (2014-2016) and the Conference on Retroviruses and Opportunistic Infections (2014-2016) were also reviewed. We contacted the authors of 15 studies to clarify definitions, obtain additional data, and remove duplications.

Type of studies

We included randomised controlled trials (RCTs) and observational studies that reported the outcomes of second-line ART in sub-Saharan Africa with viral load measured at least annually. We excluded studies with fewer than 20 participants to avoid small sample size bias, and participants outside sub-Saharan Africa in international trials. We excluded studies without defined criteria for switching to second-line ART. For studies reporting the prevalence of drug resistance at second-line ART failure, we required that an unbiased selection method for resistance testing was applied, whereby either all patients meeting a defined viral load threshold, or a random selection were tested.

Types of participants

Eligible studies investigated HIV-1 positive participants aged >10 years[3] who received first-line ART with two NRTIs and one NNRTI for ≥ 6 months prior to switching to second-line ART, defined as ≥ 2 NRTIs with a ritonavir-boosted PI. Clinical, immunological or virological criteria for switching to second-line ART were accepted, provided the criteria were clearly defined.

Analyses

The intention to treat (ITT) analysis described outcomes for all patients commencing second-line ART. Participants without virological data were categorised as: lost to follow up (no contact for ≥ 90 days since the last visit); died; transferred to another care provider; or missing data. The on-treatment (OT) analysis provided outcomes for participants that remained under follow-up with available viral load results. For participants of observational studies that had

commenced second-line ART but had not been in the study long enough to reach the virological analysis window, outcomes were imputed in proportion to the remaining participants in the cohort using a missing-at-random assumption. Data prior to imputation are presented in Supplementary Tables 2-3.

Virological outcomes

The primary outcome was virological suppression, defined as plasma HIV-1 RNA <400 copies/ml after 48 and 96 weeks of second-line ART, with a 24-week window period to allow for variations across studies (e.g., measurements taken between weeks 36 and 60 were accepted for the 48 week outcome). The 400 copies/ml threshold was chosen to reflect the most commonly used definition of virological suppression in studies from the region. Outcomes were further categorised as low level viraemia (400-1000 copies/ml) and virological failure as per WHO-definition (>1000 copies/ml).[3]

A secondary analysis explored how detection of NRTI resistance prior to starting second-line ART influenced virological outcomes at week 48. We included studies with available data using an OT analysis. The overall activity of the second-line regimen was scored as either full or partial using the Stanford Resistance algorithm (v8.2).[9]

Resistance

The prevalence of major protease resistance mutations according to the Stanford Resistance algorithm (v8.2)[9] after 48 and 96 weeks was calculated as a proportion of the population that underwent resistance testing at failure.

Data extraction

Following the literature search and removal of duplicate citations, two reviewers (AS, MS) independently screened the abstracts of retrieved records to include all potentially relevant articles, and then independently reviewed the full text of the remaining articles. Disputes about inclusion of articles were resolved through discussion with recourse to a third reviewer (AG). AS and MS independently extracted data from the studies.

Quality assessment

We conducted this study according to recommendations from the Preferred reporting Items for Systematic Reviews and Meta-Analyses.[10] The quality of included articles was assessed

using a modified version of a quality appraisal tool (Supplementary Material). The review was registered with PROSPERO (CRD42016048985).

Statistical analysis

Agreement between reviewers was assessed using Cohen's kappa statistic. Confidence intervals (CIs) were calculated using the Wilson method. Proportions were stabilised using the Freeman-Tukey arcsine square root transformation and a pooled proportion calculated using the DerSimonian-Laird random effects model.[11] To assess the effect of pre-existing NRTI resistance on virological outcomes, we calculated the odds ratio (OR) of pooled rates of virological suppression at 48 weeks among patients receiving fully active regimens compared to those on partially active regimens, using a DerSimonian-Laird random effects model. We reported the I^2 statistic, where I^2 is interpreted as the proportion of variability in the treatment estimate attributable to between-study heterogeneity rather than sampling error. We assessed potential publication bias by visual inspection of funnel plots and by Egger's test.[12]

To determine the effect on virological outcomes of study design (randomised vs. observational), median CD4 cell count, year of study and duration of first-line ART, we performed meta-regression analysis using a restricted maximum-likelihood estimator mixed effects model. Analyses were conducted in Stata version 14.2 (College Station, USA).

RESULTS

Data selection and quality assessment: virological outcome studies

Following removal of duplicates, we screened 3525 abstracts and selected 206 full articles for review; the selection showed good agreement between reviewers (Cohen's kappa 0.70 [95% CI 0.63, 0.76]). Twenty articles describing 15 studies met the inclusion criteria (Figure 1), comprising five RCTs,[6, 13-18] five prospective observational studies,[19-25] and five retrospective observational studies.[26-31] Six studies reported from multinational cohorts.[13-17, 19, 23] Data were available from 11/48 (23%) sub-Saharan African countries, with study locations in west, central, east and southern Africa (Figure 2, Table 1).

Assessment of study quality is shown in Supplementary Table 4. The size of the initial first-line ART population, the rate of first-line ART failure, and the rate of switching to second-line ART were poorly described. The NRTIs used in first- and second-line regimens were inconsistently reported. The rate of adverse events and the contribution of tolerability to treatment discontinuation were not reported in most studies. In one study, criteria for starting second-line ART were at risk of performance bias as they included a requirement for regular attendance at clinic.[20] Sensitivity analysis excluding this trial from the ITT and OT analyses did not significantly alter pooled estimates. There was no evidence of publication bias on inspection of funnel plots and by Egger's test of asymmetry at 48 or 96 weeks ($p=0.16$ and 0.19 respectively) (Supplementary Figure 1).

Outcomes of second-line ART

The median duration of first-line ART prior to starting second-line ART varied from 13 to 49 months (Table 1). Estimates of the rate of switching from first to second-line ART were calculable for 8 studies and ranged from 6 to 47 per 1000 patient-years. All studies used twice-daily lopinavir/ritonavir; one RCT randomised one third of participants to ritonavir-boosted darunavir (800mg once daily).[15] By ITT, virological suppression rates were 69.3% (95% CI 58.2, 79.3) among 4558 participants from 14 studies at week 48, and 61.5% (47.2, 74.9) among 2145 participants from 8 studies at week 96 (Figure 3, Supplementary Tables 2-3). In the OT analysis, suppression rates were 82.7% (76.9, 87.8) among 3626 participants from 15 studies at week 48, and 84.8% (78.8, 89.9) among 1090 participants from 8 studies at week 96 (Figure 4, Supplementary Table 5) (Figure 4). The rate of virological failure according to the WHO

definition (>1000 copies/ml), ranged between 2.5 and 26.6% of participants at 48 weeks and between 4.1 and 11.1% at 96 weeks, while low level viraemia occurred in 0 to 3.3% at 48 weeks and 0 to 5.0% at 96 weeks (Supplementary Tables 2-3).

Rates of virological suppression were significantly higher among participants of RCTs compared to observational cohorts at both week 48 (85.7% [95% CI 80.6, 90.2] vs. 58.2% [48.2, 68.0]; $p<0.001$) and week 96 (76.5% [72.8, 80.4] vs. 55.7 [43.1, 67.8]; $p<0.001$). After exclusion of missing viral load data, the difference between RCTs and observational cohorts persisted ($p<0.0001$ and $p=0.001$ at 48 and 96 weeks respectively) and estimates of virological suppression rates did not significantly change ($p=0.39$ and $p=0.58$ at 48 and 96 weeks respectively). By meta-regression analysis, neither median CD4 cell count, nor median duration of first-line ART at the time of starting second-line, nor the year of study recruitment were significantly associated with virological suppression, after adjustment for study design ($p=0.37$, $p=0.83$ and 0.95 at week 48; $p=0.91$, $p=0.74$ and $p=0.28$ at week 96, respectively).

Effect of pre-existing NRTI resistance

Resistance test results (by conventional sequencing) were available for six studies.[6, 14, 18, 20, 21, 23, 30] The likelihood of virological suppression at week 48 was lower (OR 0.31 [95% CI 0.14, 0.70]; $p=0.020$) among participants lacking evidence of NRTI resistance and therefore predicted to be receiving fully-active second-line ART, relative to those with NRTI resistance receiving partially-active second-line ART (Figure 5). Pre-existing NRTI resistance comprised predominantly the lamivudine mutation M184V (67.0 – 92.7% of participants) and thymidine analogue mutations (12.5 – 74.3%) (Supplementary Table 6).

Protease resistance at failure of second-line ART

Resistance test results (by conventional sequencing) were available from 649 participants from 13 studies, including five prospective [14, 15, 18, 23, 30] and eight cross-sectional studies.[32-39] The threshold for resistance testing ranged from 400 to 5000 copies/ml. Duration of second-line ART at the time of sequencing ranged from 6 to 37 months. Major protease resistance mutations were present in median 17% (IQR 0-25, range 0-66.7%) of patients that underwent resistance testing (Table 2). An association between the prevalence of protease resistance mutations and median duration of second line ART was observed (0-11.8% at 6-12

months to 0-28.9% at 16-24 months, and 16.7-66.7% at 27-37 months; $r^2=0.75$, $p<0.001$).
(Figure 6).

DISCUSSION

By 2030, the number of patients requiring second-line ART in sub-Saharan Africa is estimated to exceed 4 million.[8] Our pooled ITT estimates for virological suppression after 48 and 96 weeks of second-line ART were 69.3% and 61.5% respectively, demonstrating reasonable efficacy of PI-based therapy with continued NRTI use in these treatment-experienced populations. Employing similar analytical methodologies, studies from India, China, and Cambodia reported virological suppression rates ranging from 70% to 85.7% over 48-96 weeks of second-line ART.[40-42] RCTs using lopinavir/ritonavir in high-income settings reported comparable virological suppression rates among treatment-experienced patients.[43] Rates of virological suppression with first-line ART in low and middle-income countries were similar: 67.3% and 64.6% at week 48 and week 96, respectively.[44] Thus first- and second-line ART regimens show overall comparable efficacy in sub-Saharan Africa, despite the widely held assumption that sub-optimal adherence may drive first-line failure and continue to reduce responses after patients start second-line ART. Importantly, these rates fall considerably short of the 90% UNAIDS target for virological suppression. Using a high-genetic barrier regimen in first line ART (eg. with dolutegravir) may be required to meet this targets.[45] Whilst options for first-line ART are expanding, evidence is presently limited for alternative second-line options.[4]

One third of participants did not achieve virological suppression. An important reason in the ITT analysis, and a source of significant heterogeneity between studies, was the proportion of missing viral load data (excluding death or loss to follow-up) which varied from 0 to 30%, despite accepting a 24-week window. This finding implies substantial challenges in implementation of viral load monitoring. Consistent with this observation, virological outcomes were significantly better and loss to follow-up was lower among RCT participants compared to observational studies; a finding that persisted after exclusion of missing viral load data. In the EARNEST trial, therapy was delivered in a manner designed to replicate typical programme settings with broadly generalizable entry criteria, predominantly nurse-led care and without real-time viral load monitoring.[18] Outcomes were comparable to other trials with more restrictive entry criteria that used real-time viral load monitoring. Enhanced attention to patient retention, improving staffing and provision of a constant drug supply are important for

ensuring improved treatment outcomes and are likely to account for the observed differences between RCTs and observational studies.

Emergence of drug resistance is common after failure of first-line ART, and is typically characterised by mutations affecting both NNRTIs and NRTIs .[46-51] Interestingly, detection of NRTI resistance, and specifically thymidine analogue mutations (TAMs) prior to starting second-line ART, predicted significantly higher odds of virological suppression.[5, 14, 20, 21, 23, 30] An explanation is that patients who develop resistance at failure of first-line ART may have overall higher levels of adherence (and therefore greater drug selective pressure), than subjects who experience failure in the absence of resistance.[5] Importantly, the NRTIs commonly included in second-line regimens, such as zidovudine or TDF plus lamivudine, retain significant residual activity in the presence of TAMs and this is enhanced by continuation of lamivudine.[52, 53] Data from the SECOND-LINE and EARNEST studies demonstrate that apparent paradoxical benefit of NRTI resistance persists at 96-144 weeks.[5, 6]

Current reports of HIV epidemic control do not differentiate between first- and second-line ART provision and rates of second-line failure are not included among metrics of epidemic control or ART programme performance.[54] Yet between 2 and 26% of recipients of second-line ART experienced virological failure by 48 weeks. The optimal public health management of second-line failure has not been adequately defined. In South Africa, 64% of patients experiencing viraemia >400 copies/ml (median 3.5 log₁₀ copies/ml) while on second-line ART regained virological suppression 2-4 months after targeted adherence counselling.[55] This rate of re-suppression is consistent with our finding that major protease resistance mutations were uncommon at virological failure, particularly in the first 18 months of second-line ART. Emphasis on adherence is therefore necessary for second-line recipients. This should be differentiated from first-line failure where rapid emergence of NNRTI resistance is likely to limit the impact of adherence support. Effective adherence interventions may include weekly SMS reminders and targeted counselling.[56] In cohort studies from Cambodia[57], India[40] and Vietnam[58] higher rates (42-68%) of major protease mutations were observed at failure of second-line ART. This higher rate may reflect differences in adherence, duration of failing regimens or an effect of viral subtypes. In our analysis rates of PI resistance were strongly associated with increasing duration of second-line ART, suggesting duration of PI failure is an

important determinant of the need for third-line ART. Optimising the frequency of viral load monitoring and the definition of virological failure for second-line ART and defining appropriate regimens for third-line ART represent clear research priorities.

There are a number of limitations in our analysis. First, there was substantial variation in both the duration of first-line ART at the time of switching to second-line ART, and the rate of switching to second-line ART among each cohort, which was only reported in 8 studies. The lack of consistency may represent a source of reporting bias. The variation in rate of switching we observed across studies (range 6 to 47 per 1000 person years) is consistent with other low- and middle-income settings.[7] In programmes with routine viral load monitoring, rates of switching are three times higher, suggesting potentially different outcomes in programmes without monitoring.[7] Second, our analysis used aggregate rather than individual patient data and therefore it was not possible to analyse the contribution of individual risk factors to outcomes. Third, most studies applied a viral load <400 copies/ml to denote suppression. Data from South Africa demonstrate a continuum of risk of virological failure even with the lowest level of viraemia (50-199 copies/ml), indicating that low-level viraemia should trigger adherence interventions and repeat viral load. [59] Fourth, zidovudine and stavudine, previously common components of ART regimens in sub-Saharan Africa, have now been replaced by TDF, and impact on NRTI resistance profiles and second-line ART efficacy is to be demonstrated.[60]

In summary, reported rates of virological suppression among patients receiving second-line PI-based ART in sub-Saharan Africa are similar to those observed with first-line ART and comparable to the outcomes of similar regimens in Asian and Western settings. There is a significant gap in achieving the third 90 of the WHO 90-90-90 strategy for epidemic control. Reporting of second-line ART provision and rates of virological suppression among recipients is crucial to understanding of epidemic control and should be strongly encouraged. Given that over one-third of patients did not achieve virological suppression, defining the optimal definition and management of second-line ART failure, both with and without PI resistance, in this setting is an urgent research priority.

ACKNOWLEDGEMENTS

The authors would like to thank the Ndlovu Care Group, Elandsdoorn, Limpopo, South Africa, and all the participants and study teams involved in the included studies.

FUNDING

This work was supported by the Wellcome Trust [Clinical PhD Fellowships grant numbers 205157/Z/16/Z and 201251/Z/16/Z to AS and MS] and the National Institutes of Health [grant numbers AI069481, AI-27757, and AI068636 to AC].

Potential conflicts of interest.

M.A.B. reports grants and personal fees from AbbVie, grants and personal fees from Gilead, grants and personal fees from Merck, personal fees from ViiV Healthcare, outside the submitted work; G.W. reports grants from Gilead, grants from MSD, grants from Roche Diagnostics, outside the submitted work; A.C. reports grants from NIH, during the conduct of the study; personal fees from Merck & Co., personal fees from International Antiviral Society-USA, outside the submitted work; N.P. reports personal fees from AbbVie, personal fees from Janssen, personal fees from Roche, grants and non-financial support from GSK, outside the submitted work; A.M.G. reports receiving consulting honoraria from Abbvie, BMS, Gilead, Janssen, Merck, and ViiV, and speaker's fees from Abbvie, BMS, Gilead, Janssen, and ViiV. The University of Liverpool is the recipient of research grants from BMS, Gilead, Janssen, and ViiV of which A.M.G. is the principal investigator. A.M.G. is also employed as Expert Scientist by Roche Pharma Research & Early Development, Discovery & Translation Area (Immunology, Inflammation and Infectious Diseases).

REFERENCES

1. UNAIDS. Global AIDS update Geneva: Joint United Nations Programme on HIV/AIDS, **2016**.
2. Bor J, Herbst AJ, Newell ML, Barnighausen T. Increases in adult life expectancy in rural South Africa: valuing the scale-up of HIV treatment. *Science* **2013**; 339(6122): 961-5.
3. World Health Organisation. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Geneva, **2016**.
4. Kanters S, Socias ME, Paton NI, et al. Comparative efficacy and safety of second-line antiretroviral therapy for treatment of HIV/AIDS: a systematic review and network meta-analysis. *Lancet HIV* **2017**; 4(10): e433-e41.
5. Boyd MA, Moore CL, Molina JM, et al. Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis. *Lancet HIV* **2015**; 2(2): e42-51.
6. Paton NI, Kityo C, Thompson J, et al. Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial. *Lancet HIV* **2017**; 4(8): e341-e8.
7. Haas AD, Keiser O, Balestre E, et al. Monitoring and Switching of First-line Antiretroviral Therapy in sub-Saharan Africa: Collaborative Analysis of Adult Treatment Cohorts. *Lancet HIV* **2015**; 2(7): e271-e8.
8. Estill J, Ford N, Salazar-Vizcaya L, et al. The need for second-line antiretroviral therapy in adults in sub-Saharan Africa up to 2030: a mathematical modelling study. *Lancet HIV* **2016**; 3(3): e132-9.
9. Liu TF, Shafer RW. Web resources for HIV type 1 genotypic-resistance test interpretation. *Clin Infect Dis* **2006**; 42(11): 1608-18.
10. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *Bmj* **2009**; 339: b2535.
11. Higgins JPT GSe. *Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0* The Cochrane Collaboration, **2011**.
12. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *Bmj* **1997**; 315(7109): 629-34.
13. Amin J, Boyd MA, Kumarasamy N, et al. Raltegravir non-inferior to nucleoside based regimens in second-line therapy with lopinavir/ritonavir over 96 weeks: a randomised open label study for the treatment of HIV-1 infection. *PLoS One* **2015**; 10(2): e0118228.
14. Boyd M. Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in

- adults with virological failure of a standard first-line ART regimen (SECOND-LINE): A randomised, open-label, non-inferiority study. *The Lancet* **2013**; 381(9883): 2091-9.
15. Ciaffi L, Koulla-Shiro S, Sawadogo A, et al. Efficacy and safety of three second-line antiretroviral regimens in HIV-infected patients in Africa. *Aids* **2015**; 29(12): 1473-81.
 16. Gross R, Zheng L, Rosa AL, et al. Partner-based adherence intervention for second-line antiretroviral therapy (ACTG A5234): A multinational randomised trial. *Lancet HIV* Vol. 2, **2015**:e12-e9.
 17. La Rosa AM, Harrison LJ, Taiwo B, et al. Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority study. *Lancet HIV* **2016**; 3(6): e247-58.
 18. Paton NI, Kityo C, Hoppe A, et al. Assessment of second-line antiretroviral regimens for HIV therapy in Africa. *N Engl J Med* **2014**; 371(3): 234-47.
 19. Boender TS, Sigaloff KCE, Hamers RL, et al. Favorable Long-Term Outcomes of 2nd-Line ART Despite Drug-Resistant HIV-1 in Sub-Saharan Africa. *Topics in Antiviral Medicine* **2014**; 22(e-1).
 20. Castelnuovo B, John L, Lutwama F, et al. Three-year outcome data of second-line antiretroviral therapy in Ugandan adults: good virological response but high rate of toxicity. *J Int Assoc Physicians AIDS Care (Chic)* **2009**; 8(1): 52-9.
 21. Hosseinipour MC, Kumwenda JJ, Weigel R, et al. Second-line treatment in the Malawi antiretroviral programme: high early mortality, but good outcomes in survivors, despite extensive drug resistance at baseline. *HIV Med* **2010**; 11(8): 510-8.
 22. Osinusi-Adekanmbi O, Stafford K, Ukpaka A, et al. Long-term outcome of second-line antiretroviral therapy in resource-limited settings. *J Int Assoc Provid AIDS Care* **2014**; 13(4): 366-71.
 23. Sigaloff KC, Hamers RL, Wallis CL, et al. Second-line antiretroviral treatment successfully resuppresses drug-resistant HIV-1 after first-line failure: prospective cohort in Sub-Saharan Africa. *J Infect Dis* **2012**; 205(11): 1739-44.
 24. Wandeler G, Keiser O, Mulenga L, et al. Tenofovir in second-line ART in Zambia and South Africa: collaborative analysis of cohort studies. *J Acquir Immune Defic Syndr* **2012**; 61(1): 41-8.
 25. Boender TS, Hamers RL, Ondo P, et al. Protease Inhibitor Resistance in the First 3 Years of Second-Line Antiretroviral Therapy for HIV-1 in Sub-Saharan Africa. *J Infect Dis* **2016**; 214(6): 873-83.
 26. Adetunji AA, Achenbach C, Feinglass J, et al. Optimizing treatment switch for virologic failure during first-line antiretroviral therapy in resource-limited settings. *J Int Assoc Provid AIDS Care* **2013**; 12(4): 236-40.

27. Johnston V, Fielding K, Charalambous S, et al. Second-line antiretroviral therapy in a workplace and community-based treatment programme in South Africa: determinants of virological outcome. *PLoS One* **2012**; 7(5): e36997.
28. Murphy RA, Sunpath H, Castilla C, et al. Second-line antiretroviral therapy: long-term outcomes in South Africa. *J Acquir Immune Defic Syndr* **2012**; 61(2): 158-63.
29. Schoffelen AF, Wensing AM, Tempelman HA, Geelen SP, Hoepelman AI, Barth RE. Sustained virological response on second-line antiretroviral therapy following virological failure in HIV-infected patients in rural South Africa. *PLoS One* **2013**; 8(3): e58526.
30. Johnston V, Cohen K, Wiesner L, et al. Viral suppression following switch to second-line antiretroviral therapy: associations with nucleoside reverse transcriptase inhibitor resistance and subtherapeutic drug concentrations prior to switch. *J Infect Dis* **2014**; 209(5): 711-20.
31. Shearer K, Evans D, Moyo F, et al. Treatment outcomes of over 1000 patients on second-line, protease inhibitor-based antiretroviral therapy from four public-sector HIV treatment facilities across Johannesburg, South Africa. *Trop Med Int Health* **2017**; 22(2): 221-31.
32. Court R, Gordon M, Cohen K, et al. Random lopinavir concentrations predict resistance on lopinavir-based antiretroviral therapy. *Int J Antimicrob Agents* **2016**.
33. Levison JH, Orrell C, Gallien S, et al. Virologic failure of protease inhibitor-based second-line antiretroviral therapy without resistance in a large HIV treatment program in South Africa. *PLoS One* **2012**; 7(3): e32144.
34. Maiga AI, Fofana DB, Cisse M, et al. Characterization of HIV-1 antiretroviral drug resistance after second-line treatment failure in Mali, a limited-resources setting. *J Antimicrob Chemother* **2012**; 67(12): 2943-8.
35. Reynolds SJ, Laeyendecker O, Nakigozi G, et al. Antiretroviral Drug Susceptibility Among HIV-Infected Adults Failing Antiretroviral Therapy in Rakai, Uganda. *AIDS Res Hum Retroviruses* **2012**; 28(12): 1739-44.
36. Wallis CL, Mellors JW, Venter WD, Sanne I, Stevens W. Protease Inhibitor Resistance Is Uncommon in HIV-1 Subtype C Infected Patients on Failing Second-Line Lopinavir/r-Containing Antiretroviral Therapy in South Africa. *AIDS Res Treat* **2011**; 2011: 769627.
37. Ndahimana J, Riedel DJ, Muhayimpundu R, et al. HIV drug resistance mutations among patients failing second-line antiretroviral therapy in Rwanda. *Antivir Ther* **2016**; 21(3): 253-9.
38. Inzaule SC, Hamers RL, Mukui I, et al. Emergence of untreatable, multidrug-resistant HIV-1 in patients failing second-line therapy in Kenya. *Aids* **2017**; 31(10): 1495-8.
39. Schramm B, Carnimeo V, Rakesh A, et al. Cross-sectional assessment of virological failure, drug resistance and third-line regimen requirements among patients receiving second-line ART in 3 large HIV programmes in Kenya, Malawi and Mozambique. *J Int AIDS Soc* **2016**; 19.

40. Chakravarty J, Sundar S, Chourasia A, et al. Outcome of patients on second line antiretroviral therapy under programmatic condition in India. *BMC Infect Dis* **2015**; 15: 517.
41. Ferradini L, Ouk V, Segeal O, et al. High efficacy of lopinavir/r-based second-line antiretroviral treatment after 24 months of follow up at ESTHER/Calmette Hospital in Phnom Penh, Cambodia. *J Int AIDS Soc* **2011**; 14: 14.
42. Han Y, Li Y, Xie J, et al. Week 120 Efficacy of Tenofovir, Lamivudine and Lopinavir/r-Based Second-Line Antiretroviral Therapy in Treatment-Experienced HIV Patients. *PLoS One* **2015**; 10(3): e0120705.
43. Huang X, Xu Y, Yang Q, et al. Efficacy and biological safety of lopinavir/ritonavir based antiretroviral therapy in HIV-1-infected patients: a meta-analysis of randomized controlled trials. *Sci Rep* **2015**; 5: 8528.
44. Boender TS, Sigaloff KCE, McMahon JH, et al. Long-term Virological Outcomes of First-Line Antiretroviral Therapy for HIV-1 in Low- and Middle-Income Countries: A Systematic Review and Meta-analysis. *Clinical Infectious Diseases* **2015**; 61(9): 1453-61.
45. Maartens G, Meintjes G. Resistance matters in EARNEST. *The Lancet HIV* **2017**; 4(8): e323-e4.
46. Boender TS, Kityo CM, Boerma RS, et al. Accumulation of HIV-1 drug resistance after continued virological failure on first-line ART in adults and children in sub-Saharan Africa. *J Antimicrob Chemother* **2016**; 71(10): 2918-27.
47. Guichet E, Aghokeng AF, Serrano L, et al. High viral load and multidrug resistance due to late switch to second-line regimens could be a major obstacle to reach the 90-90-90 UNAIDS objectives in sub-Saharan Africa. *AIDS Res Hum Retroviruses* **2016**; 32(12): 1159-62.
48. Sigaloff KC, Hamers RL, Wallis CL, et al. Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. *J Acquir Immune Defic Syndr* **2011**; 58(1): 23-31.
49. Barth RE, Aitken SC, Tempelman H, et al. Accumulation of drug resistance and loss of therapeutic options precede commonly used criteria for treatment failure in HIV-1 subtype-C-infected patients. *Antivir Ther* **2012**; 17(2): 377-86.
50. Hamers RL, Sigaloff KCE, Wensing AM, et al. Patterns of HIV-1 Drug Resistance After First-Line Antiretroviral Therapy (ART) Failure in 6 Sub-Saharan African Countries: Implications for Second-Line ART Strategies. *Clinical Infectious Diseases* **2012**; 54(11): 1660-9.
51. Lam EP, Moore CL, Gotuzzo E, et al. Antiretroviral Resistance After First-Line Antiretroviral Therapy Failure in Diverse HIV-1 Subtypes in the SECOND-LINE Study. *AIDS Res Hum Retroviruses* **2016**; 32(9): 841-50.
52. Deeks SG, Hoh R, Neilands TB, et al. Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection. *J Infect Dis* **2005**; 192(9): 1537-44.

53. Campbell TB, Shulman NS, Johnson SC, et al. Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection. *Clin Infect Dis* **2005**; 41(2): 236-42.
54. Assefa Y, Gilks CF. Second-line antiretroviral therapy: so much to be done. *Lancet HIV* **2017**; 4(10): e424-e5.
55. Fox MP, Berhanu R, Steegen K, et al. Intensive adherence counselling for HIV-infected individuals failing second-line antiretroviral therapy in Johannesburg, South Africa. *Trop Med Int Health* **2016**; 21(9): 1131-7.
56. Mills EJ, Lester R, Thorlund K, et al. Interventions to promote adherence to antiretroviral therapy in Africa: a network meta-analysis. *The Lancet HIV* 1(3): e104-e11.
57. Nerrienet E, Nouhin J, Ngin S, et al. HIV-1 Protease Inhibitors Resistance Profiles in Patients with Virological Failure on LPV/r-based 2nd Line Regimen in Cambodia. *Journal of AIDS & Clinical Research* **2012**; S5:003.
58. Thao VP, Quang VM, Day JN, et al. High prevalence of PI resistance in patients failing second-line ART in Vietnam. *J Antimicrob Chemother* **2016**; 71(3): 762-74.
59. Hermans LE, Moorhouse M, Carmona S, et al. Effect of HIV-1 low-level viraemia during antiretroviral therapy on treatment outcomes in WHO-guided South African treatment programmes: a multicentre cohort study. *Lancet Infect Dis* **2017**; S1473-3099(17)30681-3.
60. Gregson J, Kaleebu P, Marconi VC, et al. Occult HIV-1 drug resistance to thymidine analogues following failure of first-line tenofovir combined with a cytosine analogue and nevirapine or efavirenz in sub Saharan Africa: a retrospective multi-centre cohort study. *Lancet Infect Dis* **2017**; 17(3): 296-304.

Table 1: Characteristics of included outcome studies

Reference	Design	Year	Location	N	Age, median years (IQR)	Gender (%) F)	Duration first-line ART, median months (IQR)	Frequency viral load monitoring	Second-line ART				
									Switch rate/1000 PY	Reason for switch	PI	CD4 count at start, median cells/mm ³ (IQR)	Viral load at start, median log ₁₀ copies/ml (IQR)
La Rosa[17]	RCT	2012-13	Kenya, Malawi, South Africa, Tanzania, Zimbabwe	162	38 (33-43)	50	48 (26-72)	6m	NA	VF	LPV	182 (160) ^a	4.5 (0.9) ^a
Ciaffi[15]	RCT	2010-13	Cameroon, Senegal, Burkina Faso	451	38 (32-46)	72	49 (33-69)	3m	NA	VF	LPV 64% DRV 34%	183 (87-290)	4.5 (4.0-5.1)
Paton[18]	RCT	2010-14	Uganda, Kenya, Malawi, Zimbabwe, Zambia	426	37 (31-43)	62	48 (34-65)	None	NA	VF	LPV	72 (29-143)	4.8 (4.4-5.2)
Boyd[14]/ Amin[13]	RCT	2010-14	Nigeria, South Africa	100	38 (33-45)	65	29 (19-50)	3m	NA	VF	LPV	199 (64-284)	4.2 (3.5-4.9)
Gross[16]	RCT	2009-11	Botswana, South Africa, Uganda, Zambia, Zimbabwe	132	38 (34-45)	50	34 (20-55)	3m	NA	VF	LPV	183 (94-271)	4.3 (3.8-4.9)
Osinusi- Adekanmbi[22]	POC	2008-11	Nigeria	73	35 (30-41)	67	24 (16-32)	6m	NA	VF	LPV	121	NA
Shearer[31]	ROC	2004-12	South Africa	1150	38 (33-44)	59	19 (13-31)	6m	NA	VF	LPV	203 (114-305)	4.2 (3.6-4.8)
Schoffelen[29]	ROC	2004-10	South Africa	156	35 (29-41)	72	19 (11-31)	6m	8	VF	LPV	187 (93-299)	4.0 (3.4-4.5)
Adetunji[26]	ROC	2006-09	Nigeria	225	34 (29-40)	65	16 (12-23)	6m	11	VF	LPV	139 (58-235)	4.6 (3.9-5.2)
Wandeler[24]	POC	2006-12	South Africa	971	38 (32-45)	56	27 (17-38)	6m	NA	C/I/VF	LPV	172 (95-267)	NA
Boender[19]/ Sigaloff[23]	POC	2007-11	Kenya, Nigeria, Uganda, South Africa, Zambia, Zimbabwe	243	38 (34-45)	50	27 (15-44)	12m	32	C/I/VF	LPV	126 (66-205)	4.2 (3.2-5.0)
Murphy[28]	ROC	2006-10	South Africa	136	36 (31-43)	65	13 (7-20)	6m	10	VF	LPV	153 (89-232)	4.5 (3.8-4.9)
Johnston[27]	ROC	2003-08	South Africa	417	36 (31-44)	35	23 (15-34)	6m	6	VF	LPV	169 (97-235)	4.6 (4.1-5.1)
Hosseinipour[21]	POC	2006-08	Malawi	101	38 (32-46)	55	35 (25-49)	3m	8	VF	LPV	65 (22-173)	4.7 (4.1-5.2)
Castelnuovo[20]	POC	2004-06	Uganda	40	39 (36-43)	50	22 (19-23)	6m	47	VF	LPV	108 (43-205)	4.8 (4.0-5.4)

*Mean (SD) Abbreviations: PY= patient years; POC= prospective observational cohort; ROC= retrospective observational cohort, RCT= randomised controlled trial, NA= data not available, ART= antiretroviral therapy, VF= virological failure, C=clinical failure, I=immunological failure, LPV=lopinavir with ritonavir, DRV=darunavir with ritonavir, IQR=interquartile range

Table 2: Protease inhibitor resistance at failure of second-line ART

Reference	Study design	Year	Location	Total population, n	Second-line ART duration, months, median (IQR)	Viral load threshold for sequencing (copies/ml)	Failure population, n (%)	Resistance analysis population, n (%) ^a	Protease resistance, n (% of at-risk population) ^b	Protease resistance, n (% of those sequenced)	Major protease mutation (n)
Prospective studies											
Paton[18]	RCT	2010-14	Uganda, Kenya, Malawi, Zimbabwe, Zambia	426	24	1000	46 (10.7)	41 (89.1)	8 (2.1) ^c	8 (19.5) ^c	M46I (8) I54V (7) L76V (3) V82AF (6)
Boyd[14]	RCT	2010-14	Nigeria, South Africa	100	12	500	8 (8.0)	8 (100)	0 (0)	0 (0)	-
Ciaffi[15] ^d	RCT	2010-13	Cameroon, Burkina Faso, Senegal	451	12	1000 x 2	29 (6.4)	5 (17.2)	0 (0)	0 (0)	-
Boender[25]	POC	2007-11	Kenya, Nigeria, South Africa, Uganda, Zambia, Zimbabwe	205	12	1000	21 (10.2)	17 (81.0)	2 (1.2)	2 (11.8)	M46I (2) I54V (2) L76V(1) V82A (2) L90M (1)
				177	24	1000	26 (14.7)	21 (80.8)	6 (4.2)	6 (28.6)	M46I (5) I54V (4) L76V(2) V82A (4) I84V (1)
				90	36	1000	8 (8.9)	3 (37.5)	2 (5.9)	2 (66.7)	M46I (2) I50V (1) I54V (1) V82A (2)
Johnston[30]	POC	2003-8	South Africa	417	12	400	112 (26.8)	15 (13.4)	0 (0)	0 (0)	-
Cross-sectional observational studies											
Schramm[39]	CS	2014-15	Kenya	355	27 (23-36)	500	65 (18.3)	65 (100)	16 (4.5)	16 (24.6)	NA
Inazule[38]	CS	2010-15	Kenya	NS	37 (23-55)	1000	126 (-)	123 (97.6)	39 (-)	39 (31.7)	M46I/L (30) I54V (27) V82ATFS (25)
Court[32]	CS	2009-13	South Africa	NS	20 (13-34)	1000	164 (-)	134 (81.7)	28 (-)	28 (20.9)	M46I (22) I47VA (2) I50V (1) I54VTALM (24), L76V (19) V82A (22) I84V (2) L90M (1)
Maiga[34]	CS	2012	Mali	913	24 (6-48)	500	106 (11.6)	93 (87.7)	23 (2.9)	23 (24.7)	M46I (15) I47V/A (6) I54V (12) L76V(11) V82A (8) I84V (10) L90M (3)
Ndahimana[37]	CS	2012	Rwanda	74	31 (18-46)	1000	35 (47.3)	30 (85.7)	5 (7.9)	5 (16.7)	L33F (2) M46I (4) I54V (5) L76V (2) V82A (4) I84V (2)
Levison[33]	CS	2009	South Africa	322	17 (18) ^c	1000 x 2	43 (13.3)	33 (76.7)	0 (0)	0 (0)	-
Reynolds[35]	CS	2004-9	Uganda	65	6 (6-14)	2000	8 (12.3)	6 (75.0)	0 (0)	0 (0)	-
Wallis[36]	CS	2008	South Africa	NS	16 (7-18)	5000 x 2	75 (-)	75 (100)	5 (-)	5 (6.7)	L33F (2) M46I (4) I54SV (2) L76V (2) V82A (1) I84V (2) L90M (1)

.Abbreviations: NS not specified; RCT randomised controlled trial; VL viral load; PI protease inhibitor; NA genotype not available

^a As proportion of failure population; ^bAs proportion of total at-risk population; adjusted for proportion who underwent sequencing. Major protease resistance mutations as defined by the

Stanford HIV drug resistance database[9] ^cResistance refers to intermediate or high level resistance to lopinavir only ^dAll patients received lopinavir/ritonavir apart from Ciaffi et al; 33% were randomised to darunavir/ritonavir and the remainder received lopinavir/ritonavir ^eStandard deviation

Figure 1: Flow diagram of search strategy

Figure 2: Map of included studies

Figure 3: Forest plot of virological suppression at 48 and 96 weeks: intention to treat analysis, random effects model

Figure 4: Forest plot of virological suppression at 48 and 96 weeks: on-treatment analysis, random effects model


Figure 5: Forest plot: Odds ratio for virological suppression at 48 weeks among participants with fully-active compared to partially-active second-line ART

Partially active ART is defined as level low level or greater resistance to any component of second-line ART (Stanford database version 8.2)[9] Abbreviations: VL<400 viral load less than 400 copies/ml; OR odds ratio; CI confidence interval

Figure 6: Proportion of participants with major protease mutations according to duration of second-line ART at virological failure ^a

^a Area of circles are proportional to size of cohort failing second line. Red and dashed line are quadratic line of best fit and 95% confidence interval respectively. Major protease resistance mutations according to the Stanford HIV resistance database v8.2[9]

Figure 1: Flow diagram of search strategy



Outcomes and resistance


- Ciaffi 2010-13
- Paton 2010-14
- Boyd/Amin 2010-14
- Boender/Sigaloff 2007-11
- Johnston 2003-8

Virologic outcomes only


- La Rosa 2012-13
- Gross 2009-11
- Schoffelen 2004-10
- Osinusi-Adekanmbi 2008-11
- Shearer 2004-12
- Adetunji 2006-9
- Wandeler 2006-12
- Murphy 2006-10
- Hosseinipour 2006-8
- Castelnuovo 2004-6

Resistance only

- Schramm 2014-15
- Inazule 2010-15
- Maiga 2012
- Ndahimana 2012
- Court 2009-11
- Reynolds 2004-9
- Levison 2009
- Wallis 2008




Number of participants




Where studies did not describe the distribution of patients among multiple study sites, sample sizes have been equally distributed across study locations


A: 48 weeks




B: 96 weeks



A: 48 weeks



B: 96 weeks



Proportion with virological suppression (%)

